Mylan CFO jetting off to Israel for stock exchange meeting: Reuters

Tracy Staton Mylan is sending its CFO, John Sheehan, on the road in Israel. FiercePharma News

Glimpse of promising lymphoma responses spurs a sharp spike in Epizyme shares

John Carroll Three months after retrieving rights to the lymphoma drug EPZ-6438 from Eisai in a $ 110 million deal, Epizyme has posted a positive glimpse at the drug's efficacy ...

Generics maker Alvogen eyes faster growth after CVC-led buyout

Tracy Staton A group of investment funds has teamed up to buy generics maker Alvogen. A consortium led by CVC Capital Partners snapped up a majority stake in the NJ-based company, in ...

With IPO in mind, cancer player CytomX steps up with a $70M round

John Carroll FierceBiotech News

Drug price hawk CVS Health and the case of the $44,000 nutrition supplement

Carly Helfand CVS Health may be staring down pricey hep C drugs and forthcoming PCSK9 meds, but capsules of powdered resveratrol? Not so much. FiercePharma News

Aveo endures yet another FDA setback

Damian Garde An optimistic Aveo Oncology recently plotted a path back to Phase III with its thrice-failed cancer drug, but the FDA wants to see more data before signing off on that ...

Are CV studies worth it for diabetes meds? After Merck and Sanofi’s recent successes, some say no

Carly Helfand Some industry watchers are wondering whether those large, expensive trials–which aren't long enough to establish long-term outcomes–were worth it. FiercePharma ...

Bluebird bio builds its case for gene therapy as first sickle cell patient responds

John Carroll FierceBiotech News

Consumer group demands FDA correct ‘compounded mistake’ on Vanda’s Hetlioz label

Carly Helfand The FDA has already admitted that it made a mistake with its initial approval letter for Vanda Pharmaceuticals' sleep disorder drug early last year, a consumer advocacy ...

Biotie ups IPO as UCB exits, Targovax merges to forge Nordic I-O player, Cosmo plans IPO

Nick Paul Taylor In this week's EuroBiotech Report, Biotie Therapies, Cosmo Pharmaceuticals, Targovax and Pieris Pharmaceuticals are all advancing plans to raise cash from public ...

Pfizer in quick succession turns aside second lawsuit alleging Zoloft birth defects ties

Eric Palmer Just weeks after winning the first case to go to trial that accused Pfizer of hiding birth defect risks for the children of women who took the antidepressant Zoloft during ...

Melinta grabs $67M in pursuit of a big PhIII antibiotics finish, NDA

John Carroll A few months after raising $ 357 million to back their new biotech investment group, the ex-Elan team at Malin Corp. has helped place a $ 67 million bet on Melinta Therapeutics, ...
Page 2 of 3123
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS